ReviewStem cells (Dayton, Ohio)2015
Concise Review: Prospects of Bone Marrow Mononuclear Cells and Mesenchymal Stem Cells for Treating Status Epilepticus and Chronic Epilepsy.
Review in Stem cells (Dayton, Ohio), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 50 citations in OpenAlex.
- The Evolving Role of Mesenchymal Stem Cells and Their Exosomes in Epilepsy Management: From Bench to Bedside.Stem cells international · 2026Review
- Mesenchymal Stromal Cell Treatment Alleviates Autism Spectrum Disorder Symptoms: A Case Report.Cureus · 2025Article
- Mesenchymal stem cells for regenerative medicine in central nervous system.Frontiers in neuroscience · 2022Review
- Cell-based Therapy Approach for Drug-resistant Epilepsy.Journal of epilepsy research · 2021Article
- Mesenchymal stem cell-based therapy and exosomes in COVID-19: current trends and prospects.Stem cell research & therapy · 2021Review
- Bone marrow mononuclear cells for joint therapy: The role of macrophages in inflammation resolution and tissue repair.World journal of stem cells · 2021Review
- Bone-Derived Modulators That Regulate Brain Function: Emerging Therapeutic Targets for Neurological Disorders.Frontiers in cell and developmental biology · 2021Review
- Mesenchymal stem cells as a multimodal treatment for nervous system diseases.Stem cells translational medicine · 2020Review
- Impact of c-MYC expression on proliferation, differentiation, and risk of neoplastic transformation of human mesenchymal stromal cells.Stem cell research & therapy · 2019Article
- Targeting neurodegeneration to prevent post-traumatic epilepsy.Neurobiology of disease · 2019Review
- Nasal administration of mesenchymal stem cells restores cisplatin-induced cognitive impairment and brain damage in mice.Oncotarget · 2018Article
- Administration of Bone Marrow-Derived Mononuclear Cells Contributed to the Reduction of Hypoxic-Ischemic Brain Injury in Neonatal Rats.Frontiers in neurology · 2018Article
- Multiple Autologous Bone Marrow-Derived CD271Stem cells translational medicine · 2018Article
- Mash1-dependent Notch Signaling Pathway Regulates GABAergic Neuron-Like Differentiation from Bone Marrow-Derived Mesenchymal Stem Cells.Aging and disease · 2017Article
- Intranasal MSC-derived A1-exosomes ease inflammation, and prevent abnormal neurogenesis and memory dysfunction after status epilepticus.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Contemplating stem cell therapy for epilepsy-induced neuropsychiatric symptoms.Neuropsychiatric disease and treatment · 2017Review
- Biohybrid cochlear implants in human neurosensory restoration.Stem cell research & therapy · 2016Article
- GABA-ergic cell therapy for epilepsy: Advances, limitations and challenges.Neuroscience and biobehavioral reviews · 2016Review
- Bone Marrow-Derived Cells as a Therapeutic Approach to Optic Nerve Diseases.Stem cells international · 2016Review
- Mesenchymal and induced pluripotent stem cells: general insights and clinical perspectives.Stem cells and cloning : advances and applications · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Mononuclear cells (MNCs) and mesenchymal stem cells (MSCs) derived from the bone marrow and other sources have received significant attention as donor cells for treating various neurological disorders due to their robust neuroprotective and anti-inflammatory effects. Moreover, it is relatively easy to procure these cells from both autogenic and allogenic sources. Currently, there is considerable interest in examining the usefulness of these cells for conditions such as status epilepticus (SE) and chronic epilepsy. A prolonged seizure activity in SE triggers neurodegeneration in the limbic brain areas, which elicits epileptogenesis and evolves into a chronic epileptic state. Because of their potential for providing neuroprotection, diminishing inflammation and curbing epileptogenesis, early intervention with MNCs or MSCs appears attractive for treating SE as such effects may restrain the development of chronic epilepsy typified by spontaneous seizures and learning and memory impairments. Delayed administration of these cells after SE may also be useful for easing spontaneous seizures and cognitive dysfunction in chronic epilepsy. This concise review evaluates the current knowledge and outlook pertaining to MNC and MSC therapies for SE and chronic epilepsy. In the first section, the behavior of these cells in animal models of SE and their efficacy to restrain neurodegeneration, inflammation, and epileptogenesis are discussed. The competence of these cells for suppressing seizures and improving cognitive function in chronic epilepsy are conferred in the next section. The final segment ponders issues that need to be addressed to pave the way for clinical application of these cells for SE and chronic epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.